There is very limited data on isolated systemic relapses of @entity149 ( @entity149 ). We retrospectively reviewed the clinical characteristics and outcome of 10 @entity1 with isolated @entity262 among 209 @entity1 with @entity149 mainly treated with @entity1499 -based chemotherapy (CT) with or without @entity1161 ( @entity1161 ). Isolated systemic relapse remained rare (4.8%, 10/209 @entity1 ). Median time from initial diagnosis to relapse was 33 months (range, 3-94). Sites of relapse were mostly extranodal. Three @entity1 presented with early extra-cerebral (EC) relapse 3, 5 and 8 months from the beginning of initial treatment, respectively, and 7 @entity1 had later relapses (range, 17-94 months). Treatment at relapse included surgery alone, @entity1161 alone, CT with or without radiotherapy, or CT with autologous stem cell transplantation (ASCT). Median overall survival (OS) after relapse was 15.5 months (range, 5.8-24.5) compared to 4.6 months (range, 3.6-6.5) for @entity1 with central nervous system (CNS) relapse (p   =   0.35). In conclusion, isolated systemic relapses exist but are infrequent. Early EC relapse suggests the presence of @entity262 undetectable by conventional evaluation at initial diagnosis. @entity1 follow-up must be prolonged because systemic relapse can occur as late as 10 years after initial diagnosis. Whether EC relapses of @entity149 have a better prognosis than CNS relapses needs to be assessed in a larger cohort.

Clinical characteristics and outcome of isolated extracerebral relapses of XXXX : a case series.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic disease'] @entity149 :: ('MESH:D002493', 'Disease') :: ['PCNSL', 'primary central nervous system lymphomas'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity149 :: (MESH:D002493,Disease) :: ['primary central nervous system lymphoma']
